Higher GJB2 expression in differentiated cells was characteristic of IDH-wildtype GBMs with worse prognosis (Johnson et al, 2021), while reduced GJB2 expression and enrichment of stem-like cells was apparent in IDH-mutant gliomas with improved prognosis (Cohen et al, 2013). This evidence concerns the gene GJB2 and central nervous system cancer.